Glaukos Corp Ownership
GKOS Stock | USD 142.69 1.96 1.39% |
Shares in Circulation | First Issued 2013-03-31 | Previous Quarter 50.7 M | Current Value 55 M | Avarage Shares Outstanding 36.2 M | Quarterly Volatility 14.1 M |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Glaukos |
Glaukos Stock Ownership Analysis
About 97.0% of the company shares are owned by institutional investors. The company has Price/Earnings To Growth (PEG) ratio of 1.64. Glaukos Corp recorded a loss per share of 2.93. The entity had not issued any dividends in recent years. Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. Glaukos Corporation was incorporated in 1998 and is headquartered in San Clemente, California. Glaukos Corp operates under Medical Devices classification in the United States and is traded on New York Stock Exchange. It employs 727 people. To learn more about Glaukos Corp call Thomas Burns at 949 367 9600 or check out https://www.glaukos.com.Besides selling stocks to institutional investors, Glaukos Corp also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Glaukos Corp's stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Glaukos Corp's strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Glaukos Corp Quarterly Liabilities And Stockholders Equity |
|
Glaukos Corp Insider Trades History
Roughly 3.0% of Glaukos Corp are currently held by insiders. Unlike Glaukos Corp's institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Glaukos Corp's private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Glaukos Corp's insider trades
Glaukos Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Glaukos Corp is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Glaukos Corp backward and forwards among themselves. Glaukos Corp's institutional investor refers to the entity that pools money to purchase Glaukos Corp's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Shares | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 1.2 M | Geode Capital Management, Llc | 2024-09-30 | 1.2 M | Fred Alger Management, Llc | 2024-09-30 | 1.1 M | Driehaus Capital Management Llc | 2024-06-30 | 803.6 K | Artisan Partners Limited Partnership | 2024-09-30 | 795.2 K | Gilder Gagnon Howe & Co Llc | 2024-09-30 | 658.6 K | Charles Schwab Investment Management Inc | 2024-09-30 | 641.8 K | Loomis, Sayles & Company Lp | 2024-06-30 | 554.2 K | Wellington Management Company Llp | 2024-06-30 | 553.5 K | Blackrock Inc | 2024-06-30 | 8 M | Fmr Inc | 2024-09-30 | 6.6 M |
Glaukos Corp Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Glaukos Corp insiders, such as employees or executives, is commonly permitted as long as it does not rely on Glaukos Corp's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Glaukos Corp insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Glaukos Corp Outstanding Bonds
Glaukos Corp issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Glaukos Corp uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Glaukos bonds can be classified according to their maturity, which is the date when Glaukos Corp has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
Boeing Co 2196 Corp BondUS097023DG73 | View | |
HSBC Holdings PLC Corp BondUS404280DR76 | View | |
US377320AA45 Corp BondUS377320AA45 | View | |
MPLX LP 52 Corp BondUS55336VAL45 | View | |
GLAXOSMITHKLINE CAPITAL PLC Corp BondUS377373AH85 | View | |
Morgan Stanley 3971 Corp BondUS61744YAL20 | View | |
GLAXOSMITHKLINE CAP INC Corp BondUS377372AM97 | View | |
GLAXOSMITHKLINE CAP INC Corp BondUS377372AN70 | View |
Glaukos Corp Corporate Filings
8K | 15th of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
13A | 14th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
10Q | 5th of November 2024 Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations | ViewVerify |
F4 | 1st of November 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Glaukos Stock Analysis
When running Glaukos Corp's price analysis, check to measure Glaukos Corp's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Glaukos Corp is operating at the current time. Most of Glaukos Corp's value examination focuses on studying past and present price action to predict the probability of Glaukos Corp's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Glaukos Corp's price. Additionally, you may evaluate how the addition of Glaukos Corp to your portfolios can decrease your overall portfolio volatility.